PMC34 BIBLIOGRAPHIC REVIEW OF DISCRETE EVENTS SIMULATION STUDIES IN HEALTH TECHNOLOGY EVALUATION  by Monleon, T et al.
assumptions are explored. Further assurances of internal validity
include the replication of the model in another software. CON-
CLUSION: Approaches to model validation should be included
as part of any publication. Budgetary and time allocation should
take model validation into account given the increased impor-
tance placed on the outcomes of health economic models.
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OBJECTIVES: The use of computational models to assess thera-
peutic alternatives has been growing in importance in the eco-
nomic evaluation of health technologies and services during the
last years, becoming a more relevant and helpful tool for decision
making in health care. Until now, two types of models have been
used: decision trees and Markov chains, nevertheless, they both
show important limitations when addressing complex processes
or pathologies, and that’s why interest in, and use of discrete
event simulation(DES) is growing, specially in economic evalua-
tion and medical decision making related journals. The objective
of this study was to perform a bibliographic review of DES
studies, and to evaluate their advantages ad limitations where
compared with other broadly used decision analytic model tech-
niques. METHODS: A structured bibliographic search using
Medline, principally, was performed to search in the scientiﬁc
literature the keywords: Health technology, computer simula-
tion, economic evaluation models and discrete event simulation.
A system of selection of the search based on authors peer reviews
and expert criteria was established. RESULTS: Forty-two papers
were selected using DES alone or combined with Markov chains
and decision trees. The result reﬂects the increasing number of
the DES in after 1998, specially in the last 5 years. A classiﬁca-
tion of the selected articles was performed. These classiﬁcation
revealed the use of secondary data in these model development.
Studies come in a highest percentage from UK, USA, and
Holland, the temporal perspective was from less than 1 up to 50
years; sensitivity analysis was performed in the mentioned studies
and Simul8, Arena, MS Excel were the most frequent used soft-
wares. CONCLUSION: The results reﬂect that the use and
acceptance of DES is growing internationally in health technol-
ogy and health care analysis, so it would be an useful tool to
simulate some complicated system and processes.
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OBJECTIVES: To analyze a health resources utilization claim
database in order to derive direct health costs of treating patients
with Fibromyalgia under routine medical practice at PCS.
METHODS: A 12-month retrospective study was performed
using computerized medical records from a health provider data-
base; BSA. Analysis was conducted from a 3r-payer perspective
during the year 2006. Health resources utilization included both
those of the primary care (PC) level (drugs, complementary tests,
medical visits, etc.) and those of the specialized care (SC) as well.
SC included emergency visits, hospitalizations, and tests and
drugs prescribed by specialist. Men and women above 18-years
included in the data base (n = 63,526) were analyzed. Fibromy-
algia was diagnosed according with CIE-10 criteria. Descriptive
statistics and ANCOVA models were used. RESULTS: One-
thousand-eighty-one subjects [96.7% women, 54.2 (10.1) years]
fulﬁlled CIE-10 criteria for Fibromyalgia amongst the 63,526
database subjects: 1.7%. Charlson index was no different in
Fibromyalgia patients vs controls (the rest of sample analyzed),
p = 0.212. After adjusting by age and sex, yearly total health
costs per patient were €614 higher (+66%) on average in Fibro-
myalgia than in controls; €1,550 (95% CI: 1,341–1,760) vs.
€937 (927–945), p < 0.0001. Both PC and SC annual costs were
signiﬁcantly higher in Fibro patients; mean per patient adjusted
difference of €395 (276–513, p < 0.0001) and €219 (74–364,
p = 0.003), respectively. Total annual drug costs were consider-
ably higher in patients with Fibromyalgia; €591 (485–696) vs.
€361 (356–366), p < 0.0001. Age correlated moderate but sig-
niﬁcantly with yearly PC, drug and total per patient health costs;
r = 0.324, 0.325, and 0.278, respectively, p < 0.001 in all cases.
CONCLUSION: Compared with controls, subjects with Fibro-
myalgia were associated to higher annual total direct health costs
in the primary care setting. Drugs represented a considerable
portion of health resources costs devoted to these patients. Age,
but not sex, was associated with higher costs.
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OBJECTIVES: To analyze the impact of PRO measurements on
longitudinal direct health costs when treating Fibromyalgia
under routine medical practice at PCS. METHODS: Retrospec-
tive sub-analysis of subjects above 18-years, with Fibromyalgia
according to CIE-10, included in a claim database (BSA), who
received the point-administration of FIQ, EQ-5D and BPI ques-
tionnaires after 12-months of health resources utilization record
and deriving total health direct costs. Resources included emer-
gency visits, hospitalizations, complementary tests, drugs and
medical visits occurred both at primary (PC) and specialized care
(SC) level. RESULTS: One-thousand-eighty-one subjects [96.7%
women, 54.2 (10.1) years] fulﬁlled CIE-10 criteria for Fibromy-
algia amongst 63,526 subjects in the database. PRO question-
naires were administered to a random sample of 200 patients
[97.5% women, 53.0 (8.5) years] showing no statistically differ-
ences in health resources utilization and costs vs. the other Fibro-
myalgia patients. Patient disease impact was severe [total FIQ;
71.7 (16.9)] showing weak but signiﬁcant correlation with total
annual health costs; r = 0.202 (p = 0.004). Work/domestic-
interference BPI-item correlated signiﬁcantly, but also weak, with
PC, drugs and total health costs; r = 0.216, 0.218, 0.242, respec-
tively (p < 0.01 in all cases). BPI sleep interference correlated
slightly but signiﬁcant with total costs; r = 0.203 (p = 0.004).
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